Organization (Industry)
IBSA Institut Biochimique SA
ClinicalTrials.gov lists IBSA Institut Biochimique SA as lead sponsor of 33 trials. It has 16 active development programs and 17 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers IBSA Institut Biochimique SA: 33 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (18)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Infertility | 14 |
| Osteoarthritis | 7 |
| Osteoarthritis, Knee | 6 |
| Pain | 5 |
| Facial Pain | 2 |
Showing 5 of 18 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 21 years.
Recruitment duration, a model prediction: none of the 33 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (16)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sterile buffered solution | Osteoarthritis | Phase 3 | 1 |
| Sterile buffered solution | Osteoarthritis, Knee | Phase 3 | 1 |
| Sodium hyaluronate solution - 3.36% | Osteoarthritis | Phase 3 | 1 |
| Sodium hyaluronate solution - 3.36% | Osteoarthritis, Knee | Phase 3 | 1 |
| Chondroitin | Osteoarthritis | Phase 3 | 2 |
Showing 5 of 16 active programs.
Approved assets (17)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Sinovial | 1 |
| Proton Pump Inhibitor | 1 |
| Follitrophin alpha | 1 |
| LEVOTHYROXINE SODIUM TABLETS, | 1 |
| levothyroxine sodium capsule | 1 |
Showing 5 of 17 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 58% hit target (n=12) | 18% on time (n=11) |
Journals published in (71)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Human reproduction (Oxford, England) | 19 |
| Fertility and sterility | 17 |
| Osteoarthritis and cartilage | 11 |
| Reproductive biomedicine online | 9 |
| Arthritis and rheumatism | 6 |
Showing 5 of 71 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 7 | 1 | 2025-06-24 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 9 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 11 | 2026-08-14 |
Manufacturing and distribution sites (8)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| IBSA INSTITUT BIOCHIMIQUE SA | Pazzallo Ticino, CH | EMA, FDA, Health Canada | |
| IBSA Institut Biochimique S.A. | Montagnola, CH | EMA | |
| IBSA Institut Biochimique S.A. | Cadempino, CH | EMA, Health Canada | |
| IBSA Institut Biochimique S.A. | Cadempino, CH | EMA | |
| IBSA Institut Biochimique S.A. | Lamone, CH | EMA |
Showing 5 of 8 sites.
Latest dated events (71)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-14 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-06-24 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-09-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 71 events.
Biomarker capability evidence (50)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AMH | Trial sponsor | Named in trial inclusion criteria |
| AMH | Trial sponsor | Named in trial inclusion criteria |
| AMH | Trial collaborator | Named in trial inclusion criteria |
| CCNG1 | Trial sponsor | Named in trial inclusion criteria |
| CCNG1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 50 evidence rows.
Biomarkers this organization publishes on (5)
Shown in this order: most publications first.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.